Carregant...

Dysregulation of mTOR activity through LKB1 inactivation

Mammalian target of rapamycin (mTOR) is aberrantly activated in many cancer types, and two rapamycin derivatives are currently approved by the Food and Drug Administration (FDA) of the United States for treating renal cell carcinoma. Mechanistically, mTOR is hyperactivated in human cancers either du...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Zhou, Wei, Marcus, Adam I., Vertino, Paula M.
Format: Artigo
Idioma:Inglês
Publicat: Sun Yat-sen University Cancer Center 2013
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3845579/
https://ncbi.nlm.nih.gov/pubmed/23668926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5732/cjc.013.10086
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!